The global trabectedin market is expected to grow at a significant CAGR during the forecast period (2021-2027).  The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, to remain competitive in the marketplace. For instance, in November 2020, STADA Arzneimittel AG's subsidiary in the United Arab Emirates (UAE), STADA MENA DWC-LLC, announced a commercial licensing agreement for Yondelis (trabectedin) in Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates (UAE), and Yemen. PharmaMar received a non-disclosed upfront payment as well as subsequent remunerations, including a regulatory milestone payment, under the terms of the license and commercialization agreement. 

PharmaMar kept exclusive production rights to trabectedin and sell it to STADA for clinical and commercial use in the 15 MENA markets on an exclusive basis. This new agreement follows PharmaMar's announcement on August 26th, 2019, regarding the agreement reached with Janssen Products LP (Janssen), under which PharmaMar regained commercialization rights to the product in more than 40 countries where Yondelis has already been approved, which were previously licensed to Janssen. Yondelis is now approved for the treatment of soft tissue sarcoma and recurrent ovarian cancer in various MENA countries. STADA was granted exclusive rights to sell and distribute the product in MENA nations as a result of licensing agreement and the official transfer of marketing authorizations.In August 2020, Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has begun commercialization of Yondelis in Canada, following the receipt of a Notice of Compliance from Health Canada approving the transfer of the commercial rights to Valeo. PharmaMar S.A., based in Madrid, Spain, manufactures Yondelis (trabectedin), a new marine-derived anticancer agent. As Yondelis is a globally recognised standard of care in the treatment of soft tissue sarcoma, the goal of the company was to raise awareness of its benefits and availability throughout Canada. 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape: Johnson & Johnson Services, Inc., and Pharma Mar, S.A., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Trabectedin Market Report by Segment

By Product

    • Purity:98%-99%

    • Purity:99%

By Application

    • Breast Cancer Treatment

    • Ovarian Cancer Treatment

    • Pediatric Sarcoma Treatment

    • Others

Global Trabectedin Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa